康泰生物：预计2025年净利润同比下降63.8%—75.7%

Core Viewpoint - The company expects a significant decline in net profit for 2025, projecting a range between 49 million to 73 million yuan, representing a year-on-year decrease of 63.8% to 75.7% [1] Group 1: Financial Performance - The company reported a slight increase in operating revenue compared to the previous year [1] - The overseas business generated revenue of 98.8353 million yuan, marking a substantial year-on-year increase of 859.4% [1] Group 2: Strategic Initiatives - The company is enhancing market promotion and qualification work for new products, including freeze-dried human rabies vaccine and varicella live attenuated vaccine, to improve market share of core products [1] - The company is steadily advancing its international strategy and expanding its overseas business layout [1]